Stock CSURE-M CANNASSURE THERAPEUTICS LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Cannassure Therapeutics Ltd

Equities

CSURE-M

IL0001110134

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 07:24:54 2024-04-24 am EDT 		5-day change 1st Jan Change
1,205 ILa 0.00% Intraday chart for Cannassure Therapeutics Ltd +10.65% +149.48%
Mar. 27 Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority
CI
DanCann Pharma A/S : publishes Year-end report for 2020
AQ
Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology
AQ
Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology
AQ
DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)
AQ
Lipidor : publishes interim report for Q3 2020
AQ
Lipidor : announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology
AQ
Cannassure Therapeutics : Ltd and Lipidor AB Enter a Feasibility Study and Licence Option Agreement for Development and Sales of Topical Medical Cannabis Products Based on AKVANO Technology
PR
Lipidor (Nasdaq First North: LIPI) and Cannassure (TASE:CSURE) enter a feasibility study and licence option agreement for development and sales of topical medical cannabis products
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CSURE-M Stock
  4. News Cannassure Therapeutics Ltd